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Although the association between alopecia areata (AA),
psoriasis, and other autoimmune diseases has been
well reported in the literature, an association with
metabolic syndrome has not been reported. We pre-
sent two young women with the combination of
severe psoriasis, androgen excess, metabolic syn-
drome, thyroiditis, and AA. Both women ultimately
progressed to treatment-resistant alopecia universalis.
This constellation of autoimmunity and metabolic
syndrome presents a therapeutic challenge while high-
lighting the need for full laboratory assessment of AA
patients. Careful selection of biological treatment regi-
mens may offer therapeutic benefit for both their
psoriasis and AA while giving us experience with the
newer biologics in AA.
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PRESENTATION: PATIENT 1
Patient 1 is an 18-year-old woman with a history of psoriasis
involving her scalp and body and psoriatic arthritis since the
age of 5 years and patchy alopecia since the age of 15 years.
HISTORY
Her past medical history was remarkable for hypothyroidism,
polycystic ovarian syndrome, obesity, and elevated lipid levels.
She reported irregular periods and dark terminal hair on her
upper lip and chin. Family history was remarkable for psoriasis,
alopecia areata (AA), Hashimoto’s thyroiditis, and rheumatoid
arthritis. Stressful triggers included the death of her father 6 years
before and high anxiety related to school socialization.
EXAMINATION
Physical examination revealed an obese adolescent with a
body mass index of 33.9 kg m2. Her psoriasis involved 5% of
her body surface area in the form of erythematous scaly
plaques over bilateral shins. On her scalp were several smooth
alopecic patches. She had nail pitting.
INVESTIGATIONS
Labs were unremarkable, except for a positive anti-nuclear anti-
body and an elevated free testosterone (11.7, normal range 1–9).
MANAGEMENT
She received intralesional triamcinolone acetonide
(5 mg ml1, 4 ml per session) and initially she had full
regrowth. About 1 year later, she suddenly developed new
patches of AA. This was concomitant with extreme anxiety
about the start of her school year, a 25-pound intentional
weight loss, initiating adalimumab treatment, and recently
diagnosed hypothyroidism. Notably, her psoriasis and psori-
atic arthritis were under excellent control.
OUTCOME
The hair loss progressed to alopecia universalis within a few
weeks. She was started on diphenylcyclopropenone with no
improvement.
PRESENTATION: PATIENT 2
Patient 2 is a 29-year-old woman with a 6-year history of
pustular psoriasis and psoriatic arthritis treated with metho-
trexate, etanercept, and efalizumab.
HISTORY
Her medical history was also remarkable for obesity (body
mass index 30.4 kg m2), Hashimoto’s thyroiditis, poly-
morphic eruption of pregnancy, and atopic dermatitis.
Five years after the diagnosis of psoriasis, she developed
an abrupt onset of scalp and body hair loss even-
tually progressing to alopecia universalis. Stress triggers
included work and family difficulties (mother of four
children), birth of a child, and an extremely restrictive high
protein, low carbohydrate diet. She had lost a total of
25 pounds in the 6 weeks before the hair shedding. Her
periods were irregular. She had a strong family history
of metabolic syndrome (cardiovascular disease, obesity,
diabetes, hyperlipidemia), psoriasis, thyroid abnormalities,
and atopic dermatitis.
EXAMINATION
On physical examination, she had diffuse thinning of her scalp
hair, with background patchy alopecia, thinning of lateral
eyebrows (Figure 1), and diffuse alopecia of her arms and legs.
Her fingernails were pitted, and her big toenails were
onycholytic. Her psoriasis was mainly confined to the soles,
with well demarcated slightly erythematous plaques and
overlying thick white scales.
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INVESTIGATIONS
Laboratory investigations were all normal, except for slightly
elevated free testosterone (2.1%, normal range 0.3–1.9%).
MANAGEMENT AND OUTCOME
Her alopecia was treated with diphenylcyclopropenone,
biotin, and iron, but after several months she failed all
treatments and opted not to seek any further therapy.
DISCUSSION
The constellation of autoimmune disorders in our two patients
is interesting, and many factors come into consideration.
There is compelling evidence that patients with psoriasis and
psoriatic arthritis have a higher risk to develop other auto-
immune disorders, particularly AA, with two large population
studies demonstrating an odds ratio of 2.4 (Chu et al., 2011;
Wu et al., 2012). Both our patients had strong family histories
of autoimmunity, thus illustrating their elevated risk, and both
suffered from thyroid abnormalities, which could contribute to
their hair loss. It is interesting that in these patients, their AA
flared as their psoriasis control improved after initiating
therapy with biological agents. Ferran et al. (2011) reports
that this is often associated with a poorer prognosis. Contrary
to the initial hope that tumor necrosis factor a (TNFa) may
have a role in the pathogenesis of AA, many reports have
demonstrated the inefficiency of anti-TNFa drugs in the
treatment of AA (Strober et al., 2005).
The complex cytokine milieu continues to be elucidated in
both psoriasis and AA. It is important to keep in mind, as it
signifies how psoriasis (T helper type 17 (Th17) cytokines) can
inhibit some inflammatory processes, such as those seen in
AA (Th1). Our patients are illustrative of the phenomenon
of worsening AA after successful treatment of their psoriasis.
The Renbok phenomenon describes patients with AA and
psoriasis who regrow hair within their psoriatic plaques,
which further illustrates the complex immunological overlap
between AA and psoriasis. The immunological interplay
between psoriasis and AA must be considered when selecting
therapeutic regimens for these complex patients, in order to
avoid worsening one of their inflammatory conditions while
treating the other.
Although the association between the metabolic syndrome
and psoriasis and other autoimmune inflammatory diseases
has been extensively studied, this association has not been
studied in AA. Both of our patients fulfill the criteria for
metabolic abnormalities associated with their chronic inflam-
matory conditions. This further emphasize that dermatologists
should screen such patients for autoimmune disorders asso-
ciated with psoriasis and AA, in addition to full metabolic
panel workups to avoid missing any underlying abnormalities.
Further studies to investigate an association between AA and
increased risk of cardiovascular and metabolic diseases is
warranted.
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Figure 1. Alopecic patches involving the frontal hairline and scattered
throughout the scalp with loss of lateral eyebrow.
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